<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458512458555</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458512458555</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Topical Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prolactin in multiple sclerosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Zhornitsky</surname><given-names>Simon</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512458555">1</xref>
<xref ref-type="aff" rid="aff2-1352458512458555">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yong</surname><given-names>V Wee</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512458555">1</xref>
<xref ref-type="aff" rid="aff2-1352458512458555">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Weiss</surname><given-names>Samuel</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512458555">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Metz</surname><given-names>Luanne M</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512458555">1</xref>
<xref ref-type="aff" rid="aff2-1352458512458555">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458512458555"><label>1</label>Multiple Sclerosis Program, Department of Clinical Neurosciences, University of Calgary, Canada</aff>
<aff id="aff2-1352458512458555"><label>2</label>Hotchkiss Brain Institute, University of Calgary, Calgary, Canada</aff>
<author-notes>
<corresp id="corresp1-1352458512458555">Luanne M Metz, Foothills Medical Centre, 1403 29th Street NW, Calgary, T2N 2T9, Alberta, Canada. Email: <email>Luanne.Metz@albertahealthservices.ca</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>1</issue>
<fpage>15</fpage>
<lpage>23</lpage>
<history>
<date date-type="received">
<day>26</day>
<month>6</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>7</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Multiple sclerosis (MS) is more common among women than men. MS often goes into remission during pregnancy, when prolactin (PRL) levels are known to be high. In an animal model of demyelination, PRL promoted myelin repair, suggesting it has potential as a remyelinating therapy in MS. In this systematic review, we examined the known associations between PRL and MS, in order to elucidate its potential role in the pathophysiology and treatment of MS. A systematic search was performed in the electronic databases PubMed and EMBASE, using the keywords "prolactin" AND “multiple sclerosis.” The inclusion criteria were met by 23 studies. These studies suggested to us that elevated PRL may be more common in MS patients than in controls. Hyperprolactinemia may also be associated with clinical relapse in MS, especially among patients with hypothalamic lesions or optic neuritis; however, it is unknown if this is a cause or consequence of a relapse. Overall, most people with MS have normal PRL levels. The impact of PRL on MS outcomes remains unclear.</p>
</abstract>
<kwd-group>
<kwd>Hyperprolactinemia</kwd>
<kwd>multiple sclerosis</kwd>
<kwd>myelin</kwd>
<kwd>optic neuritis</kwd>
<kwd>pregnancy</kwd>
<kwd>prolactin</kwd>
<kwd>remyelination</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1352458512458555" sec-type="intro">
<title>Introduction</title>
<p>Multiple sclerosis (MS) is thought to be a chronic T and B cell-mediated autoimmune disorder of the central nervous system (CNS) that is associated with progressive oligodendrocyte and neuronal loss, axonal degeneration and demyelination.<sup><xref ref-type="bibr" rid="bibr1-1352458512458555">1</xref></sup> The median age of MS onset is 30 years, but the disease can begin at any age. Up to 75% of the people with MS are women; 20% have a first-degree relative with MS.<sup><xref ref-type="bibr" rid="bibr1-1352458512458555">1</xref>,<xref ref-type="bibr" rid="bibr2-1352458512458555">2</xref></sup> Furthermore, in 85% of people with MS, it begins as relapsing-remitting MS (RRMS), which is characterized by recurrent episodes of CNS inflammation, clinical symptoms (relapses) and sub-clinical events that are only detectable by magnetic resonance imaging (MRI).<sup><xref ref-type="bibr" rid="bibr1-1352458512458555">1</xref></sup> All of the above contribute toward long-term neurological disability.</p>
<p>Interestingly, a number of studies have found that MS often undergoes remission during mid to late pregnancy, and this remission correlates with a decrease in the number and size of active white matter lesions.<sup><xref ref-type="bibr" rid="bibr3-1352458512458555">3</xref></sup> The Pregnancy and Multiple Sclerosis Study data reveals a 70% reduction in relapse risk during the third trimester of pregnancy in RRMS patients; however, there was also a corresponding rebound increase in relapse risk, during the first 3 months post-partum.<sup><xref ref-type="bibr" rid="bibr4-1352458512458555">4</xref></sup> Of note: PRL, estrogen and progesterone levels are all high during pregnancy, whereas only estrogen and progesterone levels fall rapidly post-partum. Such observations may suggest that PRL drives postpartum relapses; however, in a recent observational study of 32 women, Langer-Gould et al.<sup><xref ref-type="bibr" rid="bibr5-1352458512458555">5</xref></sup> found that the act of breastfeeding, where PRL levels are expected to be high, may exert a protective influence against post-partum MS relapse. Yet 87% of women with MS who did not breastfeed exclusively during the first 2 months post-partum did have a post-partum relapse. By comparison, a relapse occurred in only 36% of the women with MS who breastfed exclusively for at least 2 months post-partum. More recently, the same authors show that 37% of 72 post-partum women who have MS, but who did not breastfeed within the 2 months post-partum did experience a relapse, compared with only 9% of women who breastfed exclusively.<sup><xref ref-type="bibr" rid="bibr6-1352458512458555">6</xref></sup> Another study, however, did not find any significant correspondence between maternal breastfeeding behaviors and post-partum MS relapses,<sup><xref ref-type="bibr" rid="bibr7-1352458512458555">7</xref></sup> although the exclusivity of breast-feeding was not examined. Thus, the association between lactogenic hormones and a possible protective effect related to post-partum breastfeeding behavior on MS relapses definitely deserves further study.</p>
<p>PRL is a lactogenic hormone that may play a role in the pathophysiology of MS. PRL is secreted predominantly by the anterior pituitary and it is regulated by both inhibitory and stimulatory inputs from hypothalamic dopamine and thyrotropin-releasing hormone (TRH), respectively.<sup><xref ref-type="bibr" rid="bibr8-1352458512458555">8</xref></sup> Interestingly, PRL is also secreted by extrapituitary tissue, including chorion and B- and T-lymphocytes. PRL-like immunoreactivity is found in a number of CNS regions, such as: hypothalamus, hippocampus, amygdala, septum, brain stem, cerebellum, spinal cord, choroid plexi and circumventricular organs. Moreover, the PRL produced by the pituitary can enter the CNS via the choroid plexi of the brain ventricles and via retrograde blood flow from the pituitary to the hypothalamus.<sup><xref ref-type="bibr" rid="bibr9-1352458512458555">9</xref></sup></p>
<p>In addition to its primary roles in mammary gland development, as well as the initiation and maintenance of lactation, PRL is believed to be involved in a number of physiological roles, including immune system modulation, cell proliferation and neuroregeneration.<sup><xref ref-type="bibr" rid="bibr8-1352458512458555">8</xref><xref ref-type="bibr" rid="bibr9-1352458512458555"/><xref ref-type="bibr" rid="bibr10-1352458512458555"/><xref ref-type="bibr" rid="bibr11-1352458512458555"/>–<xref ref-type="bibr" rid="bibr12-1352458512458555">12</xref></sup> For example, PRL possesses both pro- and anti-inflammatory properties. High levels of circulating PRL can enhance Th1 cellular activity and antigen-specific T-lymphocyte function in mice. Furthermore, mice treated with PRL show a reduction in corticosteroid immunosuppression.<sup><xref ref-type="bibr" rid="bibr12-1352458512458555">12</xref></sup> In contrast, studies show that PRL receptor (PRLR) knockout mice apparently have normal immune function.<sup><xref ref-type="bibr" rid="bibr13-1352458512458555">13</xref>,<xref ref-type="bibr" rid="bibr14-1352458512458555">14</xref></sup> Interestingly, there is also evidence that radioactively iodinated [<sup>125</sup>I]prolactin exhibits a significant level of non-specific binding to the myelinated nerve tracts within the rat brain (an effect the presence of magnesium, but not calcium, facilitates).<sup><xref ref-type="bibr" rid="bibr15-1352458512458555">15</xref></sup> Our own previous data reveals that pregnant mice have an enhanced ability to remyelinate lysolecithin-induced white matter lesions<sup><xref ref-type="bibr" rid="bibr10-1352458512458555">10</xref></sup> There is an increase in oligodendrocyte precursor cell proliferation, oligodendrocyte generation, myelin basic protein expression, and in the number of myelinated axons, and these effects are stimulated by a daily infusion of 20µg/d PRL.</p>
<p>Recently, we tested daily PRL injections (20µg/d or 100µg/d i.p.) in mice with experimental autoimmune encephalomyelitis (EAE), as well.<sup><xref ref-type="bibr" rid="bibr16-1352458512458555">16</xref></sup> Consistent with the previous literature, PRL activated leukocytes <italic>in vitro</italic>; however, the lower-dose PRL did not exacerbate the clinical course of EAE when administered prophylactically (days 0–9 after immunization) nor therapeutically (days 9–18), but the high-dose PRL significantly exacerbates EAE. In addition, we found that the combination of PRL and interferon-β (IFN-β) on days 9–18 significantly improved the clinical signs and histological scores of EAE, as compared to either treatment alone. Finally, we found that PRLR knockout mice display a significantly worse EAE course, relative to wild-type mice.<sup><xref ref-type="bibr" rid="bibr16-1352458512458555">16</xref></sup> Taken together, these results do not contraindicate the use of PRL in MS, particularly when combined with IFN-β, which may counteract a potential pro-inflammatory effect of PRL.</p>
<p>Although our data does suggest that PRL may be beneficial in treating MS relapse, results by previous studies reveal that <italic>in vivo</italic> pre-treatment with the dopamine agonists bromocriptine and dihydroergocryptine inhibit splenic lymphocyte proliferative responses, <italic>in vitro</italic>, to the immunizing antigen and to concanavalin A, significantly reducing EAE severity.<sup><xref ref-type="bibr" rid="bibr17-1352458512458555">17</xref>,<xref ref-type="bibr" rid="bibr18-1352458512458555">18</xref></sup> More recently, Esquifino et al.<sup><xref ref-type="bibr" rid="bibr19-1352458512458555">19</xref></sup> show that male rats subjected to ectopic pituitary grafts exhibited higher PRL levels after EAE induction on day 1, but lower levels on days 7, 11 and 15, without presenting any clinical signs of EAE relative to sham-operated rats. On the other hand, the same team found that upon restriction of calories the PRL levels increase, but only those rats subjected to a normal diet exhibit clinical signs of EAE.<sup><xref ref-type="bibr" rid="bibr20-1352458512458555">20</xref></sup> In the context of these apparently discrepant preclinical findings, our current systematic review examined studies that evaluated PRL in MS, or where PRL was measured in studies primarily addressing other questions, in order to elucidate the role of PRL in the pathophysiology and treatment of the disorder.</p>
</sec>
<sec id="section2-1352458512458555" sec-type="methods">
<title>Methods</title>
<p>A systematic search was performed in the electronic databases PubMed and EMBASE, using the keywords "prolactin" AND “multiple sclerosis.” To be included, we selected studies having determined PRL levels in MS patients, in a cross-sectional fashion, or using PRL as a treatment/drug challenge. All study designs (excluding case reports) of any duration are described. We excluded the abstracts and manuscripts in languages other than English.</p>
</sec>
<sec id="section3-1352458512458555" sec-type="results">
<title>Results</title>
<sec id="section4-1352458512458555">
<title>Cross-sectional studies</title>
<p>According to Matsiota et al.,<sup><xref ref-type="bibr" rid="bibr21-1352458512458555">21</xref></sup> MS patients have elevated antibody titers against PRL and numerous other antigens, relative to two other groups (<xref ref-type="table" rid="table1-1352458512458555">Table 1</xref>). Grinsted et al.<sup><xref ref-type="bibr" rid="bibr22-1352458512458555">22</xref></sup> observe significantly higher concentrations of PRL, luteinizing hormone (LH), follicle stimulating hormone (FSH), and both total and free testosterone; but lower levels of oestrone sulfate, in the serum of 14 female MS patients of reproductive age, relative to controls. Similarly, Awerbuch and Sandyk<sup><xref ref-type="bibr" rid="bibr23-1352458512458555">23</xref></sup> reveal that 21% of 14 MS patients tested have serum PRL levels above the normal range. The same authors also report that there is no association between PRL levels and disease duration, among a larger sample of 32 MS patients.<sup><xref ref-type="bibr" rid="bibr24-1352458512458555">24</xref></sup></p>
<table-wrap id="table1-1352458512458555" position="float">
<label>Table 1.</label>
<caption>
<p>Studies of prolactin in multiple sclerosis (MS)</p>
</caption>
<graphic alternate-form-of="table1-1352458512458555" xlink:href="10.1177_1352458512458555-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Published Study<break/>Authors/ Reference</th>
<th align="left"><italic>N</italic> participants (study duration)</th>
<th align="left">Gender (F:M)</th>
<th align="left">Diagnosis: % of total given as RR:SP:PP</th>
<th align="left">Treatment</th>
<th align="left">PRL level (SD) (Normal range is 0–23ng/ml)</th>
<th align="left">Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="7">Cross-sectional studies</td>
</tr>
<tr>
<td>Matsiota et al.<sup><xref ref-type="bibr" rid="bibr21-1352458512458555">21</xref></sup></td>
<td>38 MS vs. 42 other<break/>Neurological diseases vs. 9 HC</td>
<td>NR</td>
<td>NR</td>
<td>---</td>
<td>---</td>
<td>MS = elevated antibody titers against PRL and other antigens</td>
</tr>
<tr>
<td>Grinsted et al.<sup><xref ref-type="bibr" rid="bibr22-1352458512458555">22</xref></sup></td>
<td>14 MS vs. 14 HC</td>
<td>14F: 0M</td>
<td>86%:<break/>14%:<break/>---</td>
<td>---</td>
<td>F = 12.6 ng/ml (SEM = 1.6)</td>
<td>MS = elevated PRL, LH, FSH and free/total testosterone</td>
</tr>
<tr>
<td>Awerbuch and Sandyk<sup><xref ref-type="bibr" rid="bibr23-1352458512458555">23</xref></sup></td>
<td>14 MS</td>
<td>9F: 5M</td>
<td>100%;<break/>---;<break/>---</td>
<td>---</td>
<td>M + F = 59 ng/ml (19)</td>
<td>MS = elevated PRL (21%)</td>
</tr>
<tr>
<td>Sandyk and Awerbuch<sup><xref ref-type="bibr" rid="bibr24-1352458512458555">24</xref></sup></td>
<td>32 MS</td>
<td>28F: 4M</td>
<td>66%:<break/>NR:<break/>NR</td>
<td>---</td>
<td>Illness duration:<break/>
<underline>&lt;5</underline> yrs = 13.4 ng/ml (11.5)<break/>
<underline>&gt;5</underline> years = 19.8ng/ml (31.8)</td>
<td>MS = No significant relation to duration of illness</td>
</tr>
<tr>
<td>Safarinejad<sup><xref ref-type="bibr" rid="bibr25-1352458512458555">25</xref></sup></td>
<td>68 MS vs. 48 HC</td>
<td>0F: 68M</td>
<td>21%:<break/>50%:<break/>27%</td>
<td>---</td>
<td>RRMS = 8.9 ng/ml (2.9)<break/>PPMS = 9.4 ng/ml (3.1)<break/>SPMS = 10.4 ng/ml (3.2)</td>
<td>MS = elevated PRL (16%), decreased LH and testosterone; no relationship between PRL and disease activity</td>
</tr>
<tr>
<td>Moshirzadeh et al.<sup><xref ref-type="bibr" rid="bibr26-1352458512458555">26</xref></sup></td>
<td>58 MS vs. 58 HC</td>
<td>24F: 34M</td>
<td>100%:<break/>---:<break/>---</td>
<td>---</td>
<td>F = 33.2 ng/ml (5.7)<break/>M = 16.9 ng/ml (8.5)<break/>M+F = 23.6ng/ml (11)</td>
<td>MS = elevated PRL in<break/>M and F (34%)</td>
</tr>
<tr>
<td>Shafa et al.<sup><xref ref-type="bibr" rid="bibr27-1352458512458555">27</xref></sup></td>
<td>60 MS vs. 60 HC</td>
<td>20F: 40M</td>
<td>86%:<break/>8%:<break/>NR</td>
<td>---</td>
<td>F = 20.2 ng/ml (14.5)<break/>M = 14.2ng/ml (11.5)</td>
<td>MS = elevated PRL</td>
</tr>
<tr>
<td>Nabavi et al.<sup><xref ref-type="bibr" rid="bibr28-1352458512458555">28</xref></sup></td>
<td>58 MS vs. 58 HC</td>
<td>58F: 0M</td>
<td>76%:<break/>21%:<break/>3%</td>
<td>---</td>
<td>F = 26.3 ng/ml (17.2)</td>
<td>MS = more hyperprolactinemia and elevated LH</td>
</tr>
<tr>
<td>Harirchian et al.<sup><xref ref-type="bibr" rid="bibr29-1352458512458555">29</xref></sup></td>
<td>43 MS vs. 43 HC</td>
<td>31F: 12M</td>
<td>84%:<break/>9%:<break/>5%</td>
<td>---</td>
<td>F = 17.8 ng/ml (10.9)<break/>M = 12.6 ng/ml (9.5)</td>
<td>MS = normal PRL; noassociation between PRL and disease activity</td>
</tr>
<tr>
<td>Yamasaki et al.<sup><xref ref-type="bibr" rid="bibr30-1352458512458555">30</xref></sup></td>
<td>32 Asian MS vs. 35 Western MS<break/>vs.<break/>16 other neurologic vs. 22 HC</td>
<td>48F: 19M</td>
<td>100%:<break/>---:<break/>---</td>
<td>---</td>
<td>F-AMS = 23.1 ng/ml<break/>F-WMS = 10.8 ng/ml<break/>M-AMS = 4.5 ng/ml<break/>W-MS = 4.6ng/ml</td>
<td>Asian MS = elevated PRL among females (22%); association between PRL, relapse and optic neuritis or Asian MS</td>
</tr>
<tr>
<td>Orbach et al.<sup><xref ref-type="bibr" rid="bibr31-1352458512458555">31</xref></sup></td>
<td>150 MS vs. other autoimmune</td>
<td>See ref<sup><xref ref-type="bibr" rid="bibr32-1352458512458555">32</xref></sup></td>
<td>See ref<sup><xref ref-type="bibr" rid="bibr32-1352458512458555">32</xref></sup></td>
<td>---</td>
<td>See ref<sup><xref ref-type="bibr" rid="bibr32-1352458512458555">32</xref></sup></td>
<td>MS = less hyperprolactinemia (7%) than other autoimmune have diseases (PM and SLE)</td>
</tr>
<tr>
<td>Da Costa et al.<sup><xref ref-type="bibr" rid="bibr32-1352458512458555">32</xref></sup></td>
<td>150 MS vs. 100 HC</td>
<td>96F: 54M</td>
<td>90%:<break/>4%:<break/>4%</td>
<td>---</td>
<td>M + F = 5.1 ng/ml (5.9)</td>
<td>MS = elevated PRL associated with SPMS and immunomodulatory treatment</td>
</tr>
<tr>
<td>Markianos et al.<sup><xref ref-type="bibr" rid="bibr33-1352458512458555">33</xref></sup></td>
<td>72 RRMS vs. 80 CIS vs. 74 HC</td>
<td>93F: 59M</td>
<td>47%:<break/>NR:<break/>NR</td>
<td>---</td>
<td>F-RRMS = 9.6 ng/ml (4.5)<break/>F-CIS = 7.8 ng/ml (3.7)<break/>M-RRMS = 5.8 ng/ml (2.7)<break/>M-CIS = 5.1ng/ml (2)</td>
<td>MS = elevated PRL in female RRMS; also normal PRL in male RRMS and CIS; no association between PRL and disease activity</td>
</tr>
<tr>
<td colspan="7"><italic>Short-term experimental studies</italic></td>
</tr>
<tr>
<td>Azar and Yamout<sup><xref ref-type="bibr" rid="bibr34-1352458512458555">34</xref></sup></td>
<td>12 MS vs. 12 HC</td>
<td>11F: 1M</td>
<td>100%:<break/>---:<break/>---</td>
<td>TRH 200µg</td>
<td>M + F = 10.2ng/ml (SEM 1.6)</td>
<td>MS = elevated PRL at baseline and in response to TRH</td>
</tr>
<tr>
<td>Kira et al.<sup><xref ref-type="bibr" rid="bibr35-1352458512458555">35</xref></sup></td>
<td>27 MS vs. 22 HC</td>
<td>6F: 3M</td>
<td>82%:<break/>NR:<break/>NR</td>
<td>BRP 2.5mg<break/>TRH 200µg<break/>SLP 100mg<break/>DOPA 500mg</td>
<td>F = 19.2 ng/ml (20.7)<break/>M = 10.2 ng/ml (6.1)</td>
<td>MS = elevated PRL (33%); associated with relapse and hypothalamic lesions</td>
</tr>
<tr>
<td>Wei and<break/>Lightman<sup><xref ref-type="bibr" rid="bibr36-1352458512458555">36</xref></sup></td>
<td>25 MS vs. 4 other neurologic vs. 9 HC</td>
<td>14F: 11M</td>
<td>36%:<break/>44%:<break/>20%</td>
<td>TRH 200µg<break/>GnRH 100µg<break/>ACTH 250µg<break/>DEX 1mg</td>
<td>NR</td>
<td>MS = normal PRL; lower testosterone lower testosterone in males, lower estradiol in females</td>
</tr>
<tr>
<td>Heesen et al.<sup><xref ref-type="bibr" rid="bibr38-1352458512458555">38</xref></sup></td>
<td>35 MS vs. 15 HC</td>
<td>27F: 8M</td>
<td>100%:<break/>---:<break/>---</td>
<td>Stress challenge</td>
<td>M + F = 21 ng/ml (14.6)</td>
<td>MS = elevated PRL, NE and DA; larger PRL decline in stressed MS patients</td>
</tr>
<tr>
<td>Heesen et al.<sup><xref ref-type="bibr" rid="bibr39-1352458512458555">39</xref></sup></td>
<td>132 MS<xref ref-type="table-fn" rid="table-fn3-1352458512458555">*</xref> vs. 17 HC</td>
<td>83F: 49M</td>
<td>27%:<break/>42%:<break/>30%</td>
<td>BRP 2.5mg<break/>MET 10mg</td>
<td>M + F = 6.4ng/ml (3.5)</td>
<td>MS = normal PRL; no correlation between PRL and disease activity at baseline</td>
</tr>
<tr>
<td colspan="7"><italic>Longitudinal studies</italic></td>
</tr>
<tr>
<td>Lombardi et al.<sup><xref ref-type="bibr" rid="bibr40-1352458512458555">40</xref></sup></td>
<td>55 MS<break/>(3 months)</td>
<td>55F: 0M</td>
<td>NR</td>
<td>Various<sup>^</sup></td>
<td>F = 8.3ng/ml</td>
<td>MS = normal PRL, but lower β-estradiol, progesterone, testosterone, FSH and LH</td>
</tr>
<tr>
<td>Then Bergh et al.<sup><xref ref-type="bibr" rid="bibr41-1352458512458555">41</xref></sup></td>
<td>9 MS<break/>(6 months)</td>
<td>8F: 1M</td>
<td>100%:<break/>---:<break/>---</td>
<td>MPN 500mg<break/>DEX 1.5mg<break/>CRH 100µg</td>
<td>M + F = 10.2 ng/ml<break/>(SEM = 0.8)</td>
<td>Methylprednisolone reduced PRL; PRL positively associated with number of lesions</td>
</tr>
<tr>
<td>Then Bergh et al.<sup><xref ref-type="bibr" rid="bibr42-1352458512458555">42</xref></sup></td>
<td>8 MS<break/>(3 months)</td>
<td>4F: 4M</td>
<td>100%:<break/>---:<break/>---</td>
<td>IFN-β 30µg<break/>DEX 1.5mg<break/>CRH 100µg</td>
<td>M + F = 11.2 ng/ml<break/>(SEM = 1.7)</td>
<td>IFN-β acutely raised PRL, growth hormone, ACTH, cortisol; patients with relapse or Gd+ lesion secreted less PRL than those without</td>
</tr>
<tr>
<td>Reder and Lowy<sup><xref ref-type="bibr" rid="bibr44-1352458512458555">44</xref></sup></td>
<td>54 MS<break/>(12 months)</td>
<td>15F: 20M</td>
<td>35%:<break/>NR:<break/>NR</td>
<td>Cyclosporin A</td>
<td>F = 11.6 ng/ml (SEM = 1.7)<break/>M = 8.7 ng/ml (SEM = 0.7)</td>
<td>No effect of cyclosporin on PRL; no association between relapse and PRL levels</td>
</tr>
<tr>
<td colspan="7"><italic>Clinical trials aimed to modulate prolactin</italic></td>
</tr>
<tr>
<td>Bissay et al.<sup><xref ref-type="bibr" rid="bibr45-1352458512458555">45</xref></sup></td>
<td>18 MS<break/>(12 months)</td>
<td>10F: 8M</td>
<td>56%:<break/>NR:<break/>NR</td>
<td>BRP 2.5mg</td>
<td>NR</td>
<td>Bromocriptine markedly reduced PRL, but did not stop disease progression</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458512458555"><p>MS: multiple sclerosis; PRL: prolactin; HC: healthy controls; NR: not reported; RR: relapsing-remitting MS subtype; SP: secondary progressive MSsubtype; PP: primary progressive MS subtype; CIS: clinically isolated syndrome; F: female; M: male; SLE: systemic lupus erythematosus; PM: polymyositis; IFN-β: interferon-beta1a; BRP: bromocriptine, SLP: sulpiride, MPN: methylprednisolone; MET: metoclopramide; TRH:thyrotropin-releasing hormone; LH: luteinizing hormone; CRH: corticotrophin-releasing hormone; FSH: follicle-stimulating hormone; GnRH: gonadotropin-releasing hormone; ACTH: adrenocorticotropic hormone; DEX: dexamethasone; DOPA: L-3,4-dihydroxyphenylalanine; NE: noradrenaline, DA: dopamine; HC: healthy controls; PO: oral administration of drug; IV: intravenous administration of drug; IM: intramuscular; Gd<sup>+</sup>: gadolinium-enhanced lesions; <sup>#</sup>: if a longitudinal study; ^: mostly anticholinergics; <sup>+</sup>: pre-drug baseline levels.</p>
</fn>
<fn id="table-fn2-1352458512458555">
<p>Notes:</p>
</fn>
<fn id="table-fn3-1352458512458555">
<label>1.</label>
<p><sup>*</sup>: In this case, the correlation between disease course and PRL levels at baseline was performed on a smaller sample of 39 MS patients.</p>
</fn>
<fn id="table-fn4-1352458512458555">
<label>2.</label>
<p>All PRL values from the literature were converted to ng/ml.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Safarinejad<sup><xref ref-type="bibr" rid="bibr25-1352458512458555">25</xref></sup> observes there were significant decreases in LH and testosterone levels, and a trend towards increased PRL levels, among 68 male MS patients, relative to healthy controls; however, correlational analyses did not show a relationship between PRL levels, disease activity, Expanded Disability Status Scale (EDSS) scores, nor the number of gadolinium-enhanced lesions (Gd+) lesions. Moshirzadeh et al.<sup><xref ref-type="bibr" rid="bibr26-1352458512458555">26</xref></sup> reveal significantly elevated PRL among 58 MS patients tested, regardless of gender, and relative to healthy controls. Furthermore, Shafa et al.<sup><xref ref-type="bibr" rid="bibr27-1352458512458555">27</xref></sup> detect elevated PRL levels among both males and females with MS. On the contrary, findings by Nabavi et al.<sup><xref ref-type="bibr" rid="bibr28-1352458512458555">28</xref></sup> report only an increase in LH levels; but not in PRL, thyroid-stimulating hormone (TSH), and FSH in MS patients, relative to normal subjects; however, significantly more hyperprolactinemia was found in the MS patients. Yet another study fails to find a difference in PRL levels between MS patients and controls, or any significant relationships between PRL levels and disease activity.<sup><xref ref-type="bibr" rid="bibr29-1352458512458555">29</xref></sup></p>
<p>A comparison between 67 Japanese MS patients and 16 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) reveal that serum PRL levels are significantly elevated in women with Asian-type MS, compared with levels in those with HAM/TSP;<sup><xref ref-type="bibr" rid="bibr30-1352458512458555">30</xref></sup> however, PRL levels in women with Western-type MS (and in all three groups of men) are not statistically different. Moreover, hyperprolactinemia is associated with acute optic neuritis in both Asian- and Western-type MS patients. In addition, a comparison of PRL levels across autoimmune diseases shows a higher rate of hyperprolactinemia in patients with polymyositis and systemic lupus erythematosus, relative to patients with MS, rheumatic arthritis, systemic sclerosis and dermatomyositis.<sup><xref ref-type="bibr" rid="bibr31-1352458512458555">31</xref></sup> The same investigators also show that, among women with MS accompanied by hyperprolactinemia, 25% have secondary-progressive MS (SPMS), whereas only 3% of the women with MS who had normal PRL levels suffer from SPMS.<sup><xref ref-type="bibr" rid="bibr32-1352458512458555">32</xref></sup> Finally, one study reported PRL levels that are significantly higher among 72 female RRMS patients (but not among the males), when compared to 80 individuals with clinically-isolated syndrome and 74 healthy controls.<sup><xref ref-type="bibr" rid="bibr33-1352458512458555">33</xref></sup></p>
</sec>
<sec id="section5-1352458512458555">
<title>Short-term experimental studies</title>
<p>A study of 12 MS patients reveals significantly elevated PRL levels at baseline, as well as following TRH stimulation, as compared to healthy controls.<sup><xref ref-type="bibr" rid="bibr34-1352458512458555">34</xref></sup> Similarly, a study of 27 Japanese MS patients shows that eight had experienced a 4–13-fold increase in PRL levels over healthy controls and four of the eight patients with hyperprolactinemia had diencephalic hypothalamic lesions on MRI, whereas none of the normo-prolactinemic patients had such lesions.<sup><xref ref-type="bibr" rid="bibr35-1352458512458555">35</xref></sup> The hyperprolactinemic patients exhibit greater disability. Half of the relapsing MS patients show a rise in PRL levels specifically during the acute stage of relapse, and a decrease during the recovery/remission stage. Loading tests with TRH, sulpiride, L-DOPA, and bromocriptine confirm that the hyperprolactinemia is of hypothalamic (rather than pituitary) origin, and that none of the patients exhibit pituitary abnormalities upon MRI.<sup><xref ref-type="bibr" rid="bibr35-1352458512458555">35</xref></sup> Another study finds no significant difference in PRL between its groups, but testosterone and estradiol are lower in male and female MS patients, respectively.<sup><xref ref-type="bibr" rid="bibr36-1352458512458555">36</xref></sup> Stimulatory results suggest that the extent of hypothalamic-pituitary-adrenal (HPA) axis activation in MS is 2.5-fold that of normal individuals, which is a level comparable to activation in rheumatoid arthritis patients.<sup><xref ref-type="bibr" rid="bibr37-1352458512458555">37</xref></sup> In a similar vein, Heesen et al.<sup><xref ref-type="bibr" rid="bibr38-1352458512458555">38</xref></sup> reveals that MS patients have a significant elevation of PRL, noradrenalin and dopamine (but not elevated adrenocorticotropic hormone [ACTH], cortisol, or adrenaline), relative to controls; however, while both groups showed a decline in PRL and cortisol levels during stress conditions (e.g. public speaking), the decline in PRL was significantly greater in the MS patients, versus the controls. In another study, the same group fails to find significant differences in PRL secretion between MS patients and controls, plus there was no relationship between PRL levels and disease activity, nor EDSS score.<sup><xref ref-type="bibr" rid="bibr39-1352458512458555">39</xref></sup></p>
</sec>
<sec id="section6-1352458512458555">
<title>Longitudinal studies</title>
<p>Hormonal analyses among 55 women at baseline and after 3 months reveals that 20 patients exhibited abnormally low levels of hormones at the second visit, including: β-estradiol, progesterone, free testosterone, FSH and LH.<sup><xref ref-type="bibr" rid="bibr40-1352458512458555">40</xref></sup> Yet the PRL levels are within normal limits. Furthermore, there is evidence that a single intravenous infusion of methylprednisolone can significantly reduce the number of Gd+ lesions seen in nine MS patients, relative to a pooled dataset of 83 untreated patients.<sup><xref ref-type="bibr" rid="bibr41-1352458512458555">41</xref></sup> Interestingly, plasma PRL shows a parallel decline that is correlated with the number of Gd+ lesions. The same team also shows that a single IFN-β injection results in marked elevation of plasma growth hormone, ACTH, PRL, and cortisol, after 2–6 hours.<sup><xref ref-type="bibr" rid="bibr42-1352458512458555">42</xref></sup> These responses generally normalized at the 3-month follow-up, while the patient was still receiving IFN-β. This result corresponds to data from healthy controls showing that acute IFN-β1b was able to transiently elevate plasma PRL, cortisol, growth hormone, epinephrine and norepinephrine.<sup><xref ref-type="bibr" rid="bibr43-1352458512458555">43</xref></sup> Furthermore, the authors found that patients who experienced a relapse or had a contrast-enhancing lesion secreted less PRL after IFN-β treatment, compared to those without evidence of active disease.<sup><xref ref-type="bibr" rid="bibr42-1352458512458555">42</xref></sup> Finally, one study did not find a change in PRL levels among 54 MS patients, following treatment with the immunosuppressant cyclosporin A, and did not find an association between clinical relapses and high PRL levels.<sup><xref ref-type="bibr" rid="bibr44-1352458512458555">44</xref></sup> Throughout that study, females exhibit significantly higher PRL levels than males.</p>
</sec>
<sec id="section7-1352458512458555">
<title>Clinical trials aiming to modulate prolactin</title>
<p>Only one clinical trial exists that aimed to alter PRL levels. Bissay et al.<sup><xref ref-type="bibr" rid="bibr45-1352458512458555">45</xref></sup> demonstrate, in an uncontrolled clinical trial involving 18 MS patients, that treatment for 1 year with bromocriptine (2.5mg b.i.d.) does successfully reduce PRL levels in all patients, but fails to stop disease progression. They report no exacerbation of MS.</p>
</sec></sec>
<sec id="section8-1352458512458555" sec-type="discussion">
<title>Discussion</title>
<p>None of the studies included in this review are randomized clinical trials, so consequently, they do not permit us to establish a causal relationship between PRL and MS. Nevertheless, these studies suggest that PRL elevation is more common in MS patients than in healthy controls, and that perhaps it is more common in SPMS and during a MS relapse. On the other hand, the collected research indicates that hyperprolactinemia is not specific to MS; and it may, in fact, be significantly more common in other autoimmune disorders, such as polymyositis and systemic lupus erythematosus<sup><xref ref-type="bibr" rid="bibr31-1352458512458555">31</xref></sup> (the latter may be partially responsive to bromocriptine therapy).<sup><xref ref-type="bibr" rid="bibr46-1352458512458555">46</xref></sup> Currently, the mechanism responsible for the elevated PRL levels is unclear. Studies included here also suggest that elevated PRL levels are more likely among pre-menopausal women than among men.<sup><xref ref-type="bibr" rid="bibr22-1352458512458555">22</xref>,<xref ref-type="bibr" rid="bibr30-1352458512458555">30</xref>,<xref ref-type="bibr" rid="bibr44-1352458512458555">44</xref></sup> This finding may be explained by the fact that pre-menopausal women already have higher mean circulating PRL levels.<sup><xref ref-type="bibr" rid="bibr9-1352458512458555">9</xref></sup> Additionally, studies indicate that elevation of PRL may be part of a nonspecific HPA axis dysregulation, due to demyelination and/or neurodegeneration. Indeed, a number of studies found elevations in growth hormone, ACTH, cortisol, FSH, LH, testosterone, noradrenalin and dopamine in MS patients, relative to controls.<sup><xref ref-type="bibr" rid="bibr22-1352458512458555">22</xref>,<xref ref-type="bibr" rid="bibr28-1352458512458555">28</xref>,<xref ref-type="bibr" rid="bibr38-1352458512458555">38</xref>,<xref ref-type="bibr" rid="bibr42-1352458512458555">42</xref></sup></p>
<p>It is noteworthy that among healthy subjects, even psychosocial stress led to significant increases in plasma PRL, ACTH, cortisol, heart rate, and systolic/diastolic blood pressure.<sup><xref ref-type="bibr" rid="bibr47-1352458512458555">47</xref></sup> Similarly, Sobrinho<sup><xref ref-type="bibr" rid="bibr48-1352458512458555">48</xref></sup> reports that evocation of emotional memories under hypnosis among healthy volunteers results in significantly more PRL, cortisol and growth hormone peaks with relation to relaxation-only conditions. Surprisingly, however, there is a negative correlation between the peaks of PRL and those of cortisol, so that the former was associated with evocation of anger, whereas the latter was associated with surprise and intimidation. Thus, PRL may represent an alternative mechanism to cortisol for coping with psychosocial stress.<sup><xref ref-type="bibr" rid="bibr48-1352458512458555">48</xref></sup> All together, these results imply that PRL elevation in MS patients may reflect several conditions: demyelination/neurodegeneration of the HPA axis, higher prevalence of psychosocial stress, or an enhanced sensitivity to psychosocial stressors.</p>
<p>Additionally, studies suggest that hyperprolactinemia may be associated with relapse in MS, especially among patients with hypothalamic lesions and patients with optic neuritis. One possible explanation for these findings is that hypothalamic lesions cause hyperprolactinemia, due to the loss of inhibitory function of the hypothalamus on PRL secretion. A recent study found that, compared to patients with longitudinally-extensive myelopathy due to neuromyelitis optica, patients with MS exhibit a significantly higher incidence of hypothalamic lesions (0% versus 13%, respectively); an incidence that corresponds to the often-documented ~10–20% rate of hyperprolactinemia in MS.<sup><xref ref-type="bibr" rid="bibr23-1352458512458555">23</xref>,<xref ref-type="bibr" rid="bibr25-1352458512458555">25</xref>,<xref ref-type="bibr" rid="bibr30-1352458512458555">30</xref>,<xref ref-type="bibr" rid="bibr31-1352458512458555">31</xref></sup> In addition, post-mortem studies reveal that hypothalamic lesions are associated with more severe MS, which may explain the elevated rate of hyperprolactinemia seen among SPMS patients.<sup><xref ref-type="bibr" rid="bibr32-1352458512458555">32</xref>,<xref ref-type="bibr" rid="bibr49-1352458512458555">49</xref></sup> Similarly, severe optic neuritis (and Asian-type MS) is thought to be associated with hyperprolactinemia because of damage to adjacent tuberoinfundibular dopaminergic neurons, which project from the mediobasal hypothalamus to the median eminence.<sup><xref ref-type="bibr" rid="bibr30-1352458512458555">30</xref></sup> Previous research shows that Asian-type MS may be a distinct genetic subtype of MS; characterized by fewer brain lesions on MRI, but more Gd+ spinal cord lesions, relative to patients with Western-type MS.<sup><xref ref-type="bibr" rid="bibr30-1352458512458555">30</xref>,<xref ref-type="bibr" rid="bibr35-1352458512458555">35</xref></sup> These data indicate that hyperprolactinemia may be caused by hypothalamic lesions or optic neuritis and Asian MS.</p>
<p>A potential explanation for the apparent association between hyperprolactinemia and relapse in MS is that elevated PRL levels may induce or aggravate MS relapses. In mice, we recently showed that daily injections of high-dose PRL (100µg) during the symptomatic period (day 9–18) exacerbate clinical EAE scores, but a dose that is five times lower (the pro-remyelinating dose used in Gregg et al.<sup><xref ref-type="bibr" rid="bibr10-1352458512458555">10</xref></sup>) has no adverse impact and is even beneficial, when combined with IFN-β.<sup><xref ref-type="bibr" rid="bibr16-1352458512458555">16</xref></sup> To date, however, there have been no studies that examine the effect of exogenous PRL treatment on MS, but reports of the treatment of MS patients with medications that indirectly affect PRL have produced mixed results, possibly because many changes occur concurrently. For example, established disease-modifying therapies such as IFN-β and methylprednisolone acutely increase and decrease PRL levels, respectively, but both of them reduce inflammation in MS. Furthermore, the influence of IFN-β seems to be very transient and methylprednisolone is not typically used in chronic cases. In contrast, a 1-year treatment with bromocriptine failed to stop disease progression in MS, despite markedly suppressing PRL levels.<sup><xref ref-type="bibr" rid="bibr45-1352458512458555">45</xref></sup> This last result is in direct contrast to the well-established finding that dopamine agonists significantly reduce the severity of EAE in rats.<sup><xref ref-type="bibr" rid="bibr17-1352458512458555">17</xref>,<xref ref-type="bibr" rid="bibr18-1352458512458555">18</xref></sup> As a whole, the studies reviewed fail to demonstrate the role of PRL on MS outcomes. In light of the beneficial effects that we observed in the lysolecithin and EAE models,<sup><xref ref-type="bibr" rid="bibr10-1352458512458555">10</xref>,<xref ref-type="bibr" rid="bibr16-1352458512458555">16</xref></sup> we believe future trials of PRL in MS may be warranted. Either PRL itself or medications that elevate PRL levels may be considered for future in-depth studies.</p>
<p>It is important for us to better understand the effects of PRL on immune system activation and MS relapse, because this hormone also has the potential to promote remyelination.<sup><xref ref-type="bibr" rid="bibr10-1352458512458555">10</xref></sup> Consequently, a dilemma is whether it could be used for its reparative action, without risking disease exacerbation.</p>
<p>Herein, we examined studies of PRL in MS in order to elucidate its role in the pathophysiology and treatment of this disorder. The studies included in this review suggest that PRL is elevated in some MS patients, likely due to non-specific dysregulation of the HPA axis, as a result of demyelination and/or neurodegeneration. These studies also suggest that hyperprolactinemia may be associated with clinical relapses in MS, especially among patients with hypothalamic lesions and/or optic neuritis. Although at present it is unknown if this is a cause or consequence of relapse, and the impact of PRL on MS outcomes remains unclear, we found that the literature does not suggest it would be unsafe to study PRL as a therapy against MS.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding statement</label>
<p>Simon Zhornitsky’s work was supported by the Stem Cell Network, the Canadian Institute of Health Research Drug Safety and Effectiveness Cross-Disciplinary research Training Program (grant no. 96116).</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>Drs’ Zhornitsky, Metz, and Yong have nothing to declare. Dr Weiss is on the Scientific Advisory Board of Stem Cell Therapeutics.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458512458555">
<label>1.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>JA</given-names></name>
<name><surname>Rudick</surname><given-names>RA</given-names></name>
</person-group>. <article-title>Multiple sclerosis therapeutics</article-title>. <edition>3rd ed</edition>. City: <publisher-name>Informahealthcare</publisher-name>, <year>2007</year>, <publisher-loc>London, UK</publisher-loc>.</citation>
</ref>
<ref id="bibr2-1352458512458555">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beck</surname><given-names>CA</given-names></name>
<name><surname>Metz</surname><given-names>LM</given-names></name>
<name><surname>Svenson</surname><given-names>LW</given-names></name>
<name><surname>Patten</surname><given-names>SB</given-names></name>
</person-group>. <article-title>Regional variation of multiple sclerosis prevalence in Canada</article-title>. <source>Mult Scler</source> <year>2005</year>; <volume>11</volume>: <fpage>516</fpage>–<lpage>519</lpage>.</citation>
</ref>
<ref id="bibr3-1352458512458555">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gregg</surname><given-names>C</given-names></name>
</person-group>. <article-title>Pregnancy, prolactin and white matter regeneration</article-title>. <source>J Neurol Sci</source> <year>2009</year>; <volume>285</volume>: <fpage>22</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr4-1352458512458555">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vukusic</surname><given-names>S</given-names></name>
<name><surname>Hutchinson</surname><given-names>M</given-names></name>
<name><surname>Hours</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Pregnancy and multiple sclerosis (the PRIMS study): Clinical predictors of postpartum relapse</article-title>. <source>Brain</source> <year>2004</year>; <volume>127</volume>: <fpage>1353</fpage>–<lpage>1360</lpage>.</citation>
</ref>
<ref id="bibr5-1352458512458555">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Langer-Gould</surname><given-names>A</given-names></name>
<name><surname>Huang</surname><given-names>SM</given-names></name>
<name><surname>Gupta</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis</article-title>. <source>Arch Neurol</source> <year>2009</year>; <volume>66</volume>: <fpage>958</fpage>–<lpage>963</lpage>.</citation>
</ref>
<ref id="bibr6-1352458512458555">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hellwig</surname><given-names>K</given-names></name>
<name><surname>Rockhoff</surname><given-names>M</given-names></name>
<name><surname>Gold</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Exclusive breastfeeding is beneficial in postpartum relapse rate reduction: A prospective study of 72 MS patients</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>S277</fpage>–<lpage>S505</lpage>.</citation>
</ref>
<ref id="bibr7-1352458512458555">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Portaccio</surname><given-names>E</given-names></name>
<name><surname>Ghezzi</surname><given-names>A</given-names></name>
<name><surname>Hakiki</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Breastfeeding is not related to postpartum relapses in multiple sclerosis</article-title>. <source>Neurol</source> <year>2011</year>; <volume>77</volume>: <fpage>145</fpage>–<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr8-1352458512458555">
<label>8.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Matera</surname><given-names>L</given-names></name>
<name><surname>Rapaport</surname><given-names>R</given-names></name>
</person-group>. <source>Neuroimmune biology vol 2. Growth and lactogenic hormones</source>. <edition>1st ed</edition>. <publisher-loc>New York</publisher-loc>: <publisher-name>Elsevier</publisher-name>, <year>2002</year>.</citation>
</ref>
<ref id="bibr9-1352458512458555">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freeman</surname><given-names>ME</given-names></name>
<name><surname>Kanyicska</surname><given-names>B</given-names></name>
<name><surname>Lerant</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Prolactin: Structure, function, and regulation of secretion</article-title>. <source>Physiol Rev</source> <year>2000</year>; <volume>80</volume>: <fpage>1523</fpage>–<lpage>1631</lpage>.</citation>
</ref>
<ref id="bibr10-1352458512458555">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gregg</surname><given-names>C</given-names></name>
<name><surname>Shikar</surname><given-names>V</given-names></name>
<name><surname>Larsen</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>White matter plasticity and enhanced remyelination in the maternal CNS</article-title>. <source>J Neurosci</source> <year>2007</year>; <volume>21</volume>; <fpage>1812</fpage>–<lpage>1823</lpage>.</citation>
</ref>
<ref id="bibr11-1352458512458555">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yong</surname><given-names>VW</given-names></name>
</person-group>. <article-title>Prospects of repair in multiple sclerosis</article-title>. <source>J Neurol Sci</source> <year>2009</year>; <volume>277</volume>: <fpage>S16</fpage>–<lpage>S18</lpage>.</citation>
</ref>
<ref id="bibr12-1352458512458555">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chikanza</surname><given-names>IC</given-names></name>
</person-group>. <article-title>Prolactin and neuroimmunomodulation: In vitro and in vivo observations</article-title>. <source>Ann N Y Acad Sci</source> <year>1999</year>; <volume>876</volume>: <fpage>119</fpage>–<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr13-1352458512458555">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Horseman</surname><given-names>ND</given-names></name>
<name><surname>Zhao</surname><given-names>W</given-names></name>
<name><surname>Montecino-Rodriguez</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene</article-title>. <source>EMBO J</source> <year>1997</year>; <volume>16</volume>: <fpage>6926</fpage>–<lpage>6935</lpage>.</citation>
</ref>
<ref id="bibr14-1352458512458555">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bouchard</surname><given-names>B</given-names></name>
<name><surname>Ormandy</surname><given-names>CJ</given-names></name>
<name><surname>Di Santo</surname><given-names>JP</given-names></name>
<etal/>
</person-group>. <article-title>Immune system development and function in prolactin receptor-deficient mice</article-title>. <source>J Immunol</source> <year>1999</year>; <volume>163</volume>: <fpage>576</fpage>–<lpage>582</lpage>.</citation>
</ref>
<ref id="bibr15-1352458512458555">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mangurian</surname><given-names>LP</given-names></name>
<name><surname>Walsh</surname><given-names>RJ</given-names></name>
<name><surname>Posner</surname><given-names>BI</given-names></name>
</person-group>. <article-title>Magnesium-dependent non-specific binding of [<sup>125</sup>I]prolactin to myelinated tracts in the rat central nervous system</article-title>. <source>Biochem Biophys Res Commun</source> <year>1989</year>; <volume>158</volume>: <fpage>986</fpage>–<lpage>990</lpage>.</citation>
</ref>
<ref id="bibr16-1352458512458555">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>T</given-names></name>
<name><surname>Mowbray</surname><given-names>H</given-names></name>
<name><surname>Verhaeghe</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Assessing the safety and efficacy of prolactin in EAE: A step towards a clinical trial of prolactin in multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2009</year>; <volume>15</volume>; <fpage>S151</fpage>–<lpage>S269</lpage>.</citation>
</ref>
<ref id="bibr17-1352458512458555">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Riskind</surname><given-names>PN</given-names></name>
<name><surname>Massacesi</surname><given-names>L</given-names></name>
<name><surname>Doolittle</surname><given-names>TH</given-names></name>
<etal/>
</person-group>. <article-title>The role of prolactin in autoimmune demyelination: Suppression of experimental allergic encephalomyelitis by bromocriptine</article-title>. <source>Ann Neurol</source> <year>1991</year>; <volume>29</volume>: <fpage>542</fpage>–<lpage>547</lpage>.</citation>
</ref>
<ref id="bibr18-1352458512458555">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Canonico</surname><given-names>PL</given-names></name>
<name><surname>Sortino</surname><given-names>MA</given-names></name>
<name><surname>Favit</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Dihydroergocryptine protects from acute experimental allergic encephalomyelitis in the rat</article-title>. <source>Funct Neurol</source> <year>1993</year>; <volume>8</volume>: <fpage>183</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr19-1352458512458555">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Esquifino</surname><given-names>AI</given-names></name>
<name><surname>Cano</surname><given-names>P</given-names></name>
<name><surname>Zapata</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Experimental allergic encephalomyelitis in pituitary-grafted Lewis rats</article-title>. <source>J Neuroinflamm</source> <year>2006</year>; <volume>3</volume>: <fpage>20</fpage>.</citation>
</ref>
<ref id="bibr20-1352458512458555">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Esquifino</surname><given-names>AI</given-names></name>
<name><surname>Cano</surname><given-names>P</given-names></name>
<name><surname>Jimenez</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>Experimental allergic encephalomyelitis in male Lewis rats subjected to calorie restriction</article-title>. <source>J Physiol Biochem</source> <year>2004</year>; <volume>60</volume>: <fpage>245</fpage>–<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr21-1352458512458555">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matsiota</surname><given-names>P</given-names></name>
<name><surname>Blancher</surname><given-names>A</given-names></name>
<name><surname>Doyon</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Comparative study of natural autoantibodies in the serum and cerebrospinal fluid of normal individuals and patients with multiple sclerosis and other neurological diseases</article-title>. <source>Ann Inst Pasteur Immunol</source> <year>1988</year>; <volume>139</volume>: <fpage>99</fpage>–<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr22-1352458512458555">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grinsted</surname><given-names>L</given-names></name>
<name><surname>Heltberg</surname><given-names>A</given-names></name>
<name><surname>Hagen</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Serum sex hormone and gonadotropin concentrations in premenopausal women with multiple sclerosis</article-title>. <source>J Intern Med</source> <year>1989</year>; <volume>226</volume>: <fpage>241</fpage>–<lpage>244</lpage>.</citation>
</ref>
<ref id="bibr23-1352458512458555">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Awerbuch</surname><given-names>AI</given-names></name>
<name><surname>Sandyk</surname><given-names>R</given-names></name>
</person-group>. <article-title>Prolactin secretion in multiple sclerosis</article-title>. <source>Int J Neurosci</source> <year>1991</year>; <volume>61</volume>: <fpage>145</fpage>–<lpage>148</lpage>.</citation>
</ref>
<ref id="bibr24-1352458512458555">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sandyk</surname><given-names>R</given-names></name>
<name><surname>Awerbuch</surname><given-names>GI</given-names></name>
</person-group>. <article-title>Relationship of nocturnal melatonin levels to duration and course of multiple sclerosis</article-title>. <source>Int J Neurosci</source> <year>1994</year>; <volume>75</volume>: <fpage>229</fpage>–<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr25-1352458512458555">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Safarinejad</surname><given-names>MR</given-names></name>
</person-group>. <article-title>Evaluation of endocrine profile, hypothalamic-pituitary-testis axis and semen quality in multiple sclerosis</article-title>. <source>J Neuroendocrinol</source> <year>2008</year>; <volume>20</volume>: <fpage>1368</fpage>–<lpage>1375</lpage>.</citation>
</ref>
<ref id="bibr26-1352458512458555">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moshirzadeh</surname><given-names>S</given-names></name>
<name><surname>Ghareghozli</surname><given-names>K</given-names></name>
<name><surname>Harandi</surname><given-names>AA</given-names></name>
<etal/>
</person-group>. <article-title>Serum prolactin level in patients with Relapsing–Remitting Multiple Sclerosis during relapse</article-title>. <source>J Clin Neurosci</source> <year>2012</year>; <volume>19</volume>: <fpage>622</fpage>–<lpage>623</lpage>.</citation>
</ref>
<ref id="bibr27-1352458512458555">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shafa</surname><given-names>MA</given-names></name>
<name><surname>Vakilian</surname><given-names>A</given-names></name>
<name><surname>Poorebrahimi</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Serum prolactin level in multiple sclerosis patients</article-title>. <source>JRMS</source> <volume>2006</volume>; <fpage>11</fpage>: <fpage>325</fpage>–<lpage>328</lpage>.</citation>
</ref>
<ref id="bibr28-1352458512458555">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nabavi</surname><given-names>SM</given-names></name>
<name><surname>Koupai</surname><given-names>SA</given-names></name>
<name><surname>Nejati</surname><given-names>MR</given-names></name>
<etal/>
</person-group>. <article-title>Menstrual irregularities and related plasma hormone levels in multiple sclerosis patients treated with beta interferon</article-title>. <source>Acta Medica Iranica</source> <year>2009</year>; <volume>48</volume>: <fpage>36</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr29-1352458512458555">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harirchian</surname><given-names>MH</given-names></name>
<name><surname>Sahraian</surname><given-names>MA</given-names></name>
<etal/>
</person-group>. <article-title>Serum prolactin level in patients with multiple sclerosis: A case control study</article-title>. <source>Med Sci Monit</source> <year>2006</year>; <volume>12</volume>: <fpage>177</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr30-1352458512458555">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yamasaki</surname><given-names>K</given-names></name>
<name><surname>Horiuchi</surname><given-names>I</given-names></name>
<name><surname>Minohara</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Hyperprolactinemia in optico-spinal multiple sclerosis</article-title>. <source>Intern Med</source> <year>2000</year>; <volume>39</volume>: <fpage>296</fpage>–<lpage>299</lpage>.</citation>
</ref>
<ref id="bibr31-1352458512458555">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Orbach</surname><given-names>H</given-names></name>
<name><surname>Zandman-Goddard</surname><given-names>G</given-names></name>
<name><surname>Amital</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Novel biomarkers in autoimmune diseases: Prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases</article-title>. <source>Ann NY Acad Sci</source> <year>2007</year>; <volume>1109</volume>: <fpage>385</fpage>–<lpage>400</lpage>.</citation>
</ref>
<ref id="bibr32-1352458512458555">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Da Costa</surname><given-names>R</given-names></name>
<name><surname>Szyper-Kravitz</surname><given-names>M</given-names></name>
<name><surname>Szekanecz</surname><given-names>Z</given-names></name>
<etal/>
</person-group>. <article-title>Ferritin and prolactin levels in multiple sclerosis</article-title>. <source>Isr Med Assoc J</source> <year>2011</year>; <volume>13</volume>: <fpage>91</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr33-1352458512458555">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Markianos</surname><given-names>M</given-names></name>
<name><surname>Koutsis</surname><given-names>G</given-names></name>
<name><surname>Evangelopoulos</surname><given-names>ME</given-names></name>
<etal/>
</person-group>. <article-title>Serum and cerebrospinal fluid prolactin levels in male and female patients with clinically-isolated syndrome or Relapsing–Remitting Multiple Sclerosis</article-title>. <source>J Neuroendocrinol</source> <year>2010</year>; <volume>22</volume>: <fpage>503</fpage>–<lpage>508</lpage>.</citation>
</ref>
<ref id="bibr34-1352458512458555">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Azar</surname><given-names>ST</given-names></name>
<name><surname>Yamout</surname><given-names>B</given-names></name>
</person-group>. <article-title>Prolactin secretion is increased in patients with multiple sclerosis</article-title>. <source>Endocr Res</source> <year>1999</year>; <volume>25</volume>: <fpage>207</fpage>–<lpage>214</lpage>.</citation>
</ref>
<ref id="bibr35-1352458512458555">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kira</surname><given-names>J</given-names></name>
<name><surname>Harada</surname><given-names>M</given-names></name>
<name><surname>Yamaguchi</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Hyperprolactinemia in multiple sclerosis</article-title>. <source>J Neurol Sci</source> <year>1991</year>; <volume>102</volume>: <fpage>61</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr36-1352458512458555">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wei</surname><given-names>T</given-names></name>
<name><surname>Lightman</surname><given-names>SL</given-names></name>
</person-group>. <article-title>The neuroendocrine axis in patients with multiple sclerosis</article-title>. <source>Brain</source> <year>1997</year>; <volume>120</volume>: <fpage>1067</fpage>–<lpage>1076</lpage>.</citation>
</ref>
<ref id="bibr37-1352458512458555">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neeck</surname><given-names>G</given-names></name>
<name><surname>Federlin</surname><given-names>K</given-names></name>
<name><surname>Graef</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>Adrenal secretion of cortisol in patients with rheumatoid arthritis</article-title>. <source>J Rheumatol</source> <year>1990</year>; <volume>17</volume>: <fpage>24</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr38-1352458512458555">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heesen</surname><given-names>C</given-names></name>
<name><surname>Schulz</surname><given-names>H</given-names></name>
<name><surname>Schmidt</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Endocrine and cytokine responses to acute psychological stress in multiple sclerosis</article-title>. <source>Brain Behav Immun</source> <year>2002</year>; <volume>16</volume>: <fpage>282</fpage>–<lpage>287</lpage>.</citation>
</ref>
<ref id="bibr39-1352458512458555">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heesen</surname><given-names>C</given-names></name>
<name><surname>Gold</surname><given-names>SM</given-names></name>
<name><surname>Bruhn</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Prolactin stimulation in multiple sclerosis – An indicator of disease subtypes and activity?</article-title> <source>Endocr Res</source> <year>2002</year>; <volume>28</volume>: <fpage>9</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr40-1352458512458555">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lombardi</surname><given-names>G</given-names></name>
<name><surname>Celso</surname><given-names>M</given-names></name>
<name><surname>Bartelli</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Female sexual dysfunction and hormonal status in multiple sclerosis patients</article-title>. <source>J Sex Med</source> <year>2011</year>; <volume>8</volume>: <fpage>1138</fpage>–<lpage>1146</lpage>.</citation>
</ref>
<ref id="bibr41-1352458512458555">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Then Bergh</surname><given-names>F</given-names></name>
<name><surname>Kumpfel</surname><given-names>T</given-names></name>
<name><surname>Schumann</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Monthly intravenous methylprednisolone in Relapsing–Remitting Multiple Sclerosis – Reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations</article-title>. <source>BMC Neurol</source> <year>2006</year>; <volume>6</volume>: <fpage>19</fpage>.</citation>
</ref>
<ref id="bibr42-1352458512458555">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Then Bergh</surname><given-names>F</given-names></name>
<name><surname>Kumpfel</surname><given-names>T</given-names></name>
<name><surname>Yassouridis</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Acute and chronic neuroendocrine effects of interferon-beta 1a in multiple sclerosis</article-title>. <source>Clin Endocrinol</source> <year>2007</year>; <volume>66</volume>: <fpage>295</fpage>–<lpage>303</lpage>.</citation>
</ref>
<ref id="bibr43-1352458512458555">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goebel</surname><given-names>MU</given-names></name>
<name><surname>Baase</surname><given-names>J</given-names></name>
<name><surname>Pithan</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>Acute interferon beta-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects</article-title>. <source>Psychoneuroendocrinol</source> <year>2002</year>; <volume>27</volume>: <fpage>881</fpage>–<lpage>892</lpage>.</citation>
</ref>
<ref id="bibr44-1352458512458555">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reder</surname><given-names>AT</given-names></name>
<name><surname>Lowy</surname><given-names>MT</given-names></name>
</person-group>. <article-title>Serum prolactin levels in active multiple sclerosis and during cyclosporin treatment</article-title>. <source>J Neurol Sci</source> <year>1993</year>; <volume>117</volume>: <fpage>192</fpage>–<lpage>196</lpage>.</citation>
</ref>
<ref id="bibr45-1352458512458555">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bissay</surname><given-names>V</given-names></name>
<name><surname>De Klippel</surname><given-names>N</given-names></name>
<name><surname>Herroelen</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Bromocriptine therapy in multiple sclerosis: An open label pilot study</article-title>. <source>Clin Neuropharmacol</source> <year>1994</year>; <volume>17</volume>: <fpage>473</fpage>–<lpage>476</lpage>.</citation>
</ref>
<ref id="bibr46-1352458512458555">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McMurray</surname><given-names>RW</given-names></name>
<name><surname>Allen</surname><given-names>SH</given-names></name>
<name><surname>Braun</surname><given-names>AL</given-names></name>
<etal/>
</person-group>. <article-title>Longstanding hyperprolactinemia associated with systemic lupus erythematosus: Possible hormonal stimulation of an autoimmune disease</article-title>. <source>J Rheumatol</source> <year>1994</year>; <volume>21</volume>: <fpage>843</fpage>–<lpage>850</lpage>.</citation>
</ref>
<ref id="bibr47-1352458512458555">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lennartsson</surname><given-names>AK</given-names></name>
<name><surname>Jonsdottir</surname><given-names>IH</given-names></name>
</person-group>. <article-title>Prolactin in response to acute psychosocial stress in healthy men and women</article-title>. <source>Psychoneuroendocrinol</source> <year>2011</year>; <volume>36</volume>: <fpage>1530</fpage>–<lpage>1539</lpage>.</citation>
</ref>
<ref id="bibr48-1352458512458555">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sobrinho</surname><given-names>LG</given-names></name>
</person-group>. <article-title>Prolactin, psychological stress and environment in humans: Adaptation and maladaptation</article-title>. <source>Pituitary</source> <year>2003</year>; <volume>6</volume>: <fpage>35</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr49-1352458512458555">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huitinga</surname><given-names>I</given-names></name>
<name><surname>Erkut</surname><given-names>ZA</given-names></name>
<name><surname>Van Beurden</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Impaired hypothalamus-pituitary-adrenal axis activity and more severe multiple sclerosis with hypothalamic lesions</article-title>. <source>Ann Neurol</source> <year>2004</year>; <volume>55</volume>: <fpage>37</fpage>–<lpage>45</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>